Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 2

1343 - Driver oncogene status in early-emerging lung adenocarcinoma


20 Dec 2015


Poster presentation 2


Kosuke Tanaka


Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532


K. Tanaka1, Y. Oya1, T. Yoshida1, J. Shimizu2, Y. Horio2, T. Hida2, Y. Yatabe3

Author affiliations

  • 1 Department Of Thoracic Oncology, Aichi Cancer Center Hospital, 464–8681 - Nagoya/JP
  • 2 Thoracic Oncology, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP
  • 3 Department Of Pathology And Molecular Diagnosis, Aichi Cancer Center Hospital, 464-8681 - Nagoya/JP


Abstract 1343


EGFR, Kras mutations are frequently positive in adenocarcinoma among all lung cancers. HER2, BRAF mutations or EML4-ALK, RET, ROS1 translocations are identified in lesser numbers. Although adenocarcinomas emerging in younger patients are presumably associated with some driver oncogenes including these mutations/translocations, details remain unknown.


We retrospectively screened 67 consecutive patients who were diagnosed as stage I-IV adenocarcinoma at the age of 40 years or less in 2009-2014. We analyzed clinical and genetic characteristics among them.


Out of 67 patients, 27 (40%) were male, 26 (39%) were never-smoker, and 45 (68%) were stage IV, with the median age of 36 years (range; 26-40). Fifty-five patients (82%) were identified with some driver oncogene. Thirty (45%) had EML4-ALK translocation, 19 (28%) had EGFR mutation, and 2 (3%) had Kras mutation. Most of the EGFR-mutant patients had exon 19 deletion (14/19; 74%). Furthermore, we examined rare oncogenes in 12 out of 15 triple-negative patients, which revealed three patients had HER2 mutation and two had RET translocation. Twenty-six stage IIIB-IV patients with EML4-ALK translocation received ALK-inhibitors; the median progression-free survival was 8.9 months (95% CI: 4.8-10.8 months).


82% of early-emerging adenocarcinoma was identified with some targetable driver oncogenes. Among younger populations, examination of all known driver oncogenes is recommended.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings